Abstract
A fixed combination of aliskiren (at doses of 150 mg and 300 mg) and hydrochlorothiazide (at doses of 12.5 mg and 25 mg) is indicated for use in the treatment of arterial hypertension. Aliskiren is a direct renin inhibitor that does not interfere with hormonal activity.
Hydrochlorothiazide is a classical thiazide diuretic. Their combination provides multiple benefits - potentiation of the antihypertensive activity and reduction of adverse events (particularly as a result of reduced risk of hydrochlorothiazide-induced hypokalemia and insulin resistance).
As for the tolerance, this combination is among the best tolerated antihypertensives. The drug-drug interaction risk of both agents is also very low.
From the viewpoints of efficacy and safety, the fixed combination of aliskiren and hydrochlorothiazide is an antihypertensive that meets the highest requirements.